AtriCure, Inc. logo

AtriCure, Inc. (ATRC)

Market Closed
5 Dec, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
39. 86
+0.61
+1.55%
$
1.79B Market Cap
- P/E Ratio
0% Div Yield
658,569 Volume
-0.76 Eps
$ 39.25
Previous Close
Day Range
39.03 41.12
Year Range
28.29 43.11
Want to track ATRC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 65 days

Summary

ATRC closed Friday higher at $39.86, an increase of 1.55% from Thursday's close, completing a monthly increase of 12.06% or $4.29. Over the past 12 months, ATRC stock gained 29.63%.
ATRC is not paying dividends to its shareholders.
The last earnings report, released on Oct 29, 2025, exceeded the consensus estimates by 0.1%. On average, the company has surpassed earnings expectations by 0.08%, based on the last three reports. The next scheduled earnings report is due on Feb 11, 2026.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

ATRC Chart

Similar

Lemaitre Vascular Inc.
$ 84.53
-1.37%
Innodata Inc.
$ 57.78
-0.98%
Navitas Semiconductor Corp
$ 9.48
+0.32%
Applied Optoelectronics, Inc.
$ 26.59
+1.33%
Shoals Technologies Group, Inc.
$ 8.03
+1.26%
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?

Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?

AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.

Fool | 1 week ago
Wall Street Analysts Believe AtriCure (ATRC) Could Rally 36.3%: Here's is How to Trade

Wall Street Analysts Believe AtriCure (ATRC) Could Rally 36.3%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 1 week ago
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

Zacks | 2 weeks ago

AtriCure, Inc. (ATRC) FAQ

What is the stock price today?

The current price is $39.86.

On which exchange is it traded?

AtriCure, Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is ATRC.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 1.79B.

When is the next earnings date?

The next earnings report will release on Feb 11, 2026.

Has AtriCure, Inc. ever had a stock split?

No, there has never been a stock split.

AtriCure, Inc. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Michael H. Carrel CEO
NASDAQ (NMS) Exchange
04963C209 CUSIP
US Country
1,300 Employees
- Last Dividend
- Last Split
5 Aug 2005 IPO Date

Overview

AtriCure, Inc. is a medical device company that specializes in the development, manufacturing, and sales of surgical tools designed for the ablation of cardiac tissue, the exclusion of the left atrial appendage, and the temporary blocking of pain through peripheral nerve ablation. The company operates on a global scale, with a significant presence in the United States, Europe, the Asia-Pacific region, and other international markets. Since its incorporation in 2000, AtriCure has established its headquarters in Mason, Ohio, and has expanded its market reach through a combination of direct sales staff and independent distributors. AtriCure's mission is centered around innovating cardiac care, particularly focusing on solutions to address atrial fibrillation and related conditions.

Products and Services

AtriCure boasts a diverse portfolio of products and services designed to support cardiac surgery and pain management. The company’s offerings include:

  • Isolator Synergy Clamps: These clamps are single-use, disposable products utilizing radio frequency to facilitate surgical ablation of cardiac tissue. They represent a cornerstone of AtriCure’s ablation solutions.
  • MAX Pen Device: A multifunctional pen that enables surgeons to diagnose cardiac arrhythmias, perform temporary cardiac pacing, sensing, stimulation, and ablate cardiac tissue using a single device. This innovative approach streamlines procedures by consolidating functionalities.
  • Coolrail Device: Designed to create longer linear lines of ablation, the Coolrail device simplifies the process of cardiac tissue ablation, making it more efficient for surgeons to perform complex procedures.
  • cryoICE Cryoablation System: This system allows for the creation of linear ablations of varying lengths through cryoablation, offering an alternative modality to treat cardiac arrhythmias.
  • EPi-Sense Systems: A cutting-edge solution for the treatment of persistent atrial fibrillation, the EPi-Sense System is a single-use device that represents AtriCure’s commitment to addressing complex cardiac conditions.
  • cryoSPHERE Probe: Specifically designed for pain management, the cryoSPHERE probe applies cryothermic energy to targeted peripheral nerves in the ribcage to provide temporary relief from pain.
  • AtriClip System: This system features an implantable device paired with a single-use disposable applier, intended for the exclusion of the left atrial appendage, a procedure often required in the management of atrial fibrillation.
  • LARIAT System: As a suture-based solution for soft-tissue closure, the LARIAT System exemplifies AtriCure’s innovative approach to post-procedural care, offering a novel method for securing tissue after surgical interventions.
  • Additional Tools: AtriCure also supplies a range of supplementary tools such as the Lumitip dissectors for tissue separation, Glidepath guides for clamp placement, Subtle Cannula’s to facilitate access for EPi-Sense catheters, and various reusable instruments for cardiac surgery, underlining the company’s comprehensive approach to cardiac care solutions.

Contact Information

Address: 7555 Innovation Way
Phone: 513 755 4100